Avanos Medical (AVNS) Cash from Financing Activities (2013 - 2026)

Avanos Medical has reported Cash from Financing Activities for 14 years, with the latest figure at -$3.2 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 89.0% year-over-year to -$3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.1 million (up 85.68% YoY) and the FY2025 annual result came in at -$37.0 million, up 24.64% from the prior year.
• Cash from Financing Activities eased to -$3.2 million in Q1 2026 per AVNS's latest filing, from -$2.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $105.7 million in Q1 2022 and troughed at -$114.7 million in Q4 2023.
• A 5-year average of -$7.5 million and a median of -$5.0 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 52950.0% in 2022, then sank 4057.14% in 2025.
• Over 5 years, Cash from Financing Activities stood at -$21.9 million in 2022, then slumped by 423.74% to -$114.7 million in 2023, then soared by 76.11% to -$27.4 million in 2024, then jumped by 90.15% to -$2.7 million in 2025, then slipped by 18.52% to -$3.2 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$3.2 million, -$2.7 million, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.